TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+47.93%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.08B
AUM Growth
+$1.08B
(+53%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
22.47%
Top 10 Holdings %
Top 10 Hldgs %
41.77%
Holding
136
New
30
Increased
24
Reduced
21
Closed
13
Top Buys
Top Sells
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$22.4M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$11.5M |
| 3 |
NovoCure
NVCR
|
$7.95M |
| 4 |
Intellia Therapeutics
NTLA
|
$6.02M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$5.99M |
Sector Composition
| 1 | Healthcare | 95.77% |
| 2 | Financials | 3.5% |
| 3 | Real Estate | 0.65% |
| 4 | Technology | 0.08% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Zymeworks
ZYME
$1.12B
| $11.4M | 1.06% | 1,100,000 | – | – |
|
27
GSK
GSK
$79.9B
| $11.1M | 1.03% | +300,000 | New | +$11.1M |
|
28
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $10.5M | 0.97% | 600,000 | – | – |
|
29
CytomX Therapeutics
CTMX
$336M
| $10.2M | 0.94% | 6,550,000 +100,000 | +2% | +$155K |
|
30
Ionis Pharmaceuticals
IONS
$6.79B
| $10.1M | 0.93% | 200,000 | – | – |
|
31
Beam Therapeutics
BEAM
$1.66B
| $9.53M | 0.88% | +350,000 | New | +$9.53M |
|
32
Cytokinetics
CYTK
$4.23B
| $9.18M | 0.85% | +110,000 | New | +$9.18M |
|
33
Ascendis Pharma
ASND
$11.8B
| $8.82M | 0.81% | 70,000 +60,000 | +600% | +$7.56M |
|
34
Harmony Biosciences
HRMY
$2.12B
| $8.76M | 0.81% | 271,200 | – | – |
|
|
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
| $8.27M | 0.76% | 350,000 +150,000 | +75% | +$3.54M |
|
36
Iovance Biotherapeutics
IOVA
$807M
| $8.13M | 0.75% | +1,000,000 | New | +$8.13M |
|
37
Cullinan Oncology
CGEM
$445M
| $7.86M | 0.73% | 771,138 +150,000 | +24% | +$1.53M |
|
38
Moderna
MRNA
$9.37B
| $7.63M | 0.7% | 76,700 | – | – |
|
39
Rocket Pharmaceuticals
RCKT
$354M
| $7.49M | 0.69% | 250,000 +100,000 | +67% | +$3M |
|
|
LENZ
40
LENZ Therapeutics
LENZ
$1.1B
| $6.53M | 0.6% | 2,491,780 +475,154 | +24% | +$1.24M |
|
41
BioAtla
BCAB
$26.7M
| $6.21M | 0.57% | 2,524,076 -1,254,317 | -33% | -$3.09M |
|
|
KNTE
42
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $6.17M | 0.57% | +2,601,647 | New | +$6.17M |
|
43
ADMA Biologics
ADMA
$4.12B
| $6.15M | 0.57% | 1,360,000 | – | – |
|
|
44
Intellia Therapeutics
NTLA
$1.22B
| $6.1M | 0.56% | 200,000 -197,600 | -50% | -$6.02M |
|
45
CVB Financial
CVBF
$2.77B
| $6.06M | 0.56% | 300,000 +100,000 | +50% | +$2.02M |
|
46
Verastem
VSTM
$569M
| $6.04M | 0.56% | 741,514 -150,000 | -17% | -$1.22M |
|
47
Biohaven
BHVN
$1.63B
| $5.99M | 0.55% | 140,000 | – | – |
|
|
EQC
48
DELISTED
Equity Commonwealth
EQC
| $5.76M | 0.53% | 300,000 | – | – |
|
49
Esperion Therapeutics
ESPR
$448M
| $5.53M | 0.51% | 1,850,000 | – | – |
|
|
OKUR
50
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $5.33M | 0.49% | +3,330,000 | New | +$5.33M |
|